MedPath

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Phase 1
Conditions
Human Papilloma Virus
Interventions
Biological: HPV-CTLs
Registration Number
NCT03351855
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Brief Summary

The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.

Detailed Description

Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types (HPV 16, 18, 31, 45). Around 50-80% of women are infected by HPV within their whole lives. The current treatment of HPV-positive mainly includes drug, cryotherapy, laser, microwave, surgery and so on. Some treatments are convenient, but easy to cause pain or infection and there is still a greater risk of recurrence after treatment.

Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with specific viral antigens has proven to be effective. Here, the investigators aim to evaluate the safety and efficacy of multiple infusions of HPV specific cytotoxic T lymphocytes cells in patients.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  1. Written, informed consent obtained prior to any study-specific procedures.

  2. Evidence of HPV virus activation (viral DNA) or high risk of HPV infection.

  3. Not suitable for routine treatment or invalid to antiviral drugs.

  4. Patients with viral disease symptoms and confirmed by biopsy, regardless of the level of virus DNA.

  5. Age less than 75 years.

  6. Did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics.

  7. Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 1,000/mm^3, platelet (PLT) ≥ 1,000/mm^3.

  8. Proper renal and hepatic functions (ULN denotes "upper limit of normal range"): Creatinine ≤ 2*ULN, Bilirubin ≤ 2*ULN, SGOT/ SGPT ≤ 3*ULN.

  9. If HPV-CTL is not from the patient's own, then the provider of HPV-CTL needs to meet the following criteria:

    • did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics.
    • white blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl.
  10. Human immunodeficiency virus (HIV) test was negative.

Read More
Exclusion Criteria
  1. Subject or the donor of BMT recipient infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive.
  2. Subject is albumin-intolerant.
  3. Subject with life expectancy less than 8 weeks.
  4. Subject participated in other investigational somatic cell therapies within past 30 days.
  5. Subject with positive pregnancy test result.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
HPV-CTLsHPV-CTLsAutologous or allogenic HPV specific cytotoxic lymphocytes
Primary Outcome Measures
NameTimeMethod
Safety of HPV-CTLs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events6 months

Physiological parameter (measuring cytokine response, fever, symptoms)

Secondary Outcome Measures
NameTimeMethod
Treatment Responses1 year

Disease status is defined by the biochemical markers (measuring HPV concentration and so on) to get the outcomes such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).

Viral load response6 months

The viral load response to the CTLs infusion will be assessed by HPV specific PCR of peripheral blood.

Trial Locations

Locations (1)

Shenzhen Geno-immune Medical Institute

🇨🇳

Shenzhen, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath